Karyopharm Therapeutics Inc.(KPTI)Earnings, Financials & Key RatiosKaryopharm Therapeutics Inc. (KPTI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
and the persistent negative equity of -$265.6 million suggests high insolvency risk for shareholders.
Karyopharm Therapeutics Inc. (KPTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Karyopharm Therapeutics Inc. (KPTI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $1.02vs $1.45+29.7% | $35Mvs $31M+11.7% |
| Q1 2026 | Feb 12, 2026 | $2.23vs $2.26+1.3% | $34Mvs $35M-2.9% |
| Q4 2025 | Nov 3, 2025 | $3.82vs $3.47-10.1% | $44Mvs $42M+4.7% |
| Q3 2025 | Aug 11, 2025 | $4.32vs $3.80-13.7% | $38Mvs $40M-4.1% |
Recent stock market news and headlines for Karyopharm Therapeutics Inc. (KPTI)
NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees.
Key metrics vs top competitors for Karyopharm Therapeutics Inc. (KPTI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.05 | $85.8M | -0.56 | 0.57% | -134.21% | — | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $4.75 | $301.92M | -4.03 | 0.78% | -44.79% | -147.8% | — | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Karyopharm Therapeutics Inc. (KPTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Karyopharm Therapeutics Inc. (KPTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 14, 2026·SEC
Mar 27, 2026·SEC
Mar 24, 2026·SEC
Get notified when KPTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Karyopharm Therapeutics Inc. (KPTI) stock FAQ — growth, dividends, profitability & financials explained
Karyopharm Therapeutics Inc. (KPTI) reported $151.1M in revenue for fiscal year 2025. This represents a 99320% increase from $0.2M in 2011.
Karyopharm Therapeutics Inc. (KPTI) grew revenue by 0.6% over the past year. Growth has been modest.
Karyopharm Therapeutics Inc. (KPTI) reported a net loss of $195.0M for fiscal year 2025.
Karyopharm Therapeutics Inc. (KPTI) had negative free cash flow of $59.1M in fiscal year 2025, likely due to heavy capital investments.
